MA59397B1 - Nouvelle composition à libération retardée pour administration perorale - Google Patents
Nouvelle composition à libération retardée pour administration peroraleInfo
- Publication number
- MA59397B1 MA59397B1 MA59397A MA59397A MA59397B1 MA 59397 B1 MA59397 B1 MA 59397B1 MA 59397 A MA59397 A MA 59397A MA 59397 A MA59397 A MA 59397A MA 59397 B1 MA59397 B1 MA 59397B1
- Authority
- MA
- Morocco
- Prior art keywords
- salt
- release composition
- peroral administration
- dosage forms
- new delayed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2006074.5A GB202006074D0 (en) | 2020-04-24 | 2020-04-24 | New composition |
| PCT/GB2021/050993 WO2021214487A1 (en) | 2020-04-24 | 2021-04-23 | New delayed release composition for peroral administration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA59397B1 true MA59397B1 (fr) | 2023-11-30 |
Family
ID=71080159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA59397A MA59397B1 (fr) | 2020-04-24 | 2021-04-23 | Nouvelle composition à libération retardée pour administration perorale |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US11654115B2 (OSRAM) |
| EP (2) | EP4138789B1 (OSRAM) |
| JP (2) | JP7418587B2 (OSRAM) |
| KR (1) | KR20230005239A (OSRAM) |
| CN (1) | CN115811971A (OSRAM) |
| AU (1) | AU2021258542B2 (OSRAM) |
| BR (1) | BR112022021520A2 (OSRAM) |
| CA (1) | CA3180850A1 (OSRAM) |
| DK (1) | DK4138789T3 (OSRAM) |
| ES (1) | ES2955915T3 (OSRAM) |
| FI (1) | FI4138789T3 (OSRAM) |
| GB (1) | GB202006074D0 (OSRAM) |
| HR (1) | HRP20231012T1 (OSRAM) |
| HU (1) | HUE062897T2 (OSRAM) |
| IL (1) | IL297374B2 (OSRAM) |
| LT (1) | LT4138789T (OSRAM) |
| MA (1) | MA59397B1 (OSRAM) |
| MD (1) | MD4138789T2 (OSRAM) |
| MX (1) | MX2022013069A (OSRAM) |
| PL (1) | PL4138789T3 (OSRAM) |
| PT (1) | PT4138789T (OSRAM) |
| RS (1) | RS64568B1 (OSRAM) |
| SI (1) | SI4138789T1 (OSRAM) |
| SM (1) | SMT202300289T1 (OSRAM) |
| WO (1) | WO2021214487A1 (OSRAM) |
| ZA (1) | ZA202211461B (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202004094D0 (en) * | 2020-03-20 | 2020-05-06 | Vicore Pharma Ab | New compounds and uses |
| GB202006079D0 (en) | 2020-04-24 | 2020-06-10 | Vicore Pharma Ab | New composition |
| GB202006074D0 (en) | 2020-04-24 | 2020-06-10 | Vicore Pharma Ab | New composition |
| CA3249539A1 (en) | 2022-02-10 | 2023-08-17 | Vicore Pharma Ab | USE OF BULOXIBUTID FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS |
| GB202201723D0 (en) * | 2022-02-10 | 2022-03-30 | Vicore Pharma Ab | New use |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59139317A (ja) * | 1983-01-31 | 1984-08-10 | Teisan Seiyaku Kk | 持続性のニフエジピン製剤 |
| SE9800550D0 (sv) | 1998-02-24 | 1998-02-24 | A & Science Invest Ab | A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof |
| DE60222409T2 (de) | 2001-05-31 | 2008-09-25 | Vicore Pharma Ab | Trizyklische verbindungen, nützlich als angiotensin ii agonisten |
| JP2003325642A (ja) * | 2002-05-09 | 2003-11-18 | Sansho Pharmaceutical Co Ltd | 腸溶性皮膜付き硬質空カプセルと、腸溶性皮膜付き硬質空カプセルの製造方法と、腸溶性皮膜付き硬質カプセル剤 |
| WO2005039639A2 (en) * | 2003-10-10 | 2005-05-06 | Solvay Pharmaceuticals Gmbh | Pharmaceutical composition comprising a selective i1 imidazoline receptor agonist and an angiotensin ii receptor blocker |
| WO2005123072A1 (en) * | 2004-06-14 | 2005-12-29 | Sepracor Inc. | Methods and compositions for the treatment of pulmonary diseases |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| EP2946773A1 (en) * | 2014-05-19 | 2015-11-25 | Tillotts Pharma AG | Modified release coated capsules |
| ES2793530T3 (es) * | 2014-05-19 | 2020-11-16 | Tillotts Pharma Ag | Cápsulas revestidas de liberación modificada |
| AU2016227486A1 (en) | 2015-03-02 | 2017-08-17 | Vicore Pharma Ab | Angiotensin ll receptor agonist for treating pulmonary fibrosis |
| WO2017022248A1 (ja) * | 2015-08-04 | 2017-02-09 | 富士カプセル株式会社 | 腸溶性カプセル |
| WO2017221012A1 (en) | 2016-06-21 | 2017-12-28 | Vicore Pharma Ab | Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity |
| GB201710906D0 (en) | 2017-07-06 | 2017-08-23 | Vicore Pharma Ab | Compounds and methods for treating peripheral neuropathy |
| WO2019183513A1 (en) * | 2018-03-22 | 2019-09-26 | University Of Iowa Research Foundation | Compositions and methods for the treatment and prevention of muscular dystrophy |
| JP7044360B2 (ja) * | 2018-04-02 | 2022-03-30 | 三生医薬株式会社 | ハードカプセル用コーティング剤及びそれを用いたハードカプセル剤の製造方法 |
| GB201818164D0 (en) | 2018-11-07 | 2018-12-19 | Vicore Pharma Ab | New composition |
| GB202006079D0 (en) | 2020-04-24 | 2020-06-10 | Vicore Pharma Ab | New composition |
| GB202006074D0 (en) | 2020-04-24 | 2020-06-10 | Vicore Pharma Ab | New composition |
| GB202201723D0 (en) | 2022-02-10 | 2022-03-30 | Vicore Pharma Ab | New use |
-
2020
- 2020-04-24 GB GBGB2006074.5A patent/GB202006074D0/en not_active Ceased
-
2021
- 2021-04-23 ES ES21724011T patent/ES2955915T3/es active Active
- 2021-04-23 PL PL21724011.8T patent/PL4138789T3/pl unknown
- 2021-04-23 SI SI202130057T patent/SI4138789T1/sl unknown
- 2021-04-23 MD MDE20230229T patent/MD4138789T2/ro unknown
- 2021-04-23 FI FIEP21724011.8T patent/FI4138789T3/fi active
- 2021-04-23 DK DK21724011.8T patent/DK4138789T3/da active
- 2021-04-23 CA CA3180850A patent/CA3180850A1/en active Pending
- 2021-04-23 BR BR112022021520A patent/BR112022021520A2/pt unknown
- 2021-04-23 LT LTEPPCT/GB2021/050993T patent/LT4138789T/lt unknown
- 2021-04-23 MX MX2022013069A patent/MX2022013069A/es unknown
- 2021-04-23 SM SM20230289T patent/SMT202300289T1/it unknown
- 2021-04-23 WO PCT/GB2021/050993 patent/WO2021214487A1/en not_active Ceased
- 2021-04-23 RS RS20230717A patent/RS64568B1/sr unknown
- 2021-04-23 HU HUE21724011A patent/HUE062897T2/hu unknown
- 2021-04-23 EP EP21724011.8A patent/EP4138789B1/en active Active
- 2021-04-23 HR HRP20231012TT patent/HRP20231012T1/hr unknown
- 2021-04-23 JP JP2022540547A patent/JP7418587B2/ja active Active
- 2021-04-23 MA MA59397A patent/MA59397B1/fr unknown
- 2021-04-23 KR KR1020227040358A patent/KR20230005239A/ko active Pending
- 2021-04-23 EP EP23177726.9A patent/EP4218737A1/en active Pending
- 2021-04-23 CN CN202180042664.2A patent/CN115811971A/zh active Pending
- 2021-04-23 PT PT217240118T patent/PT4138789T/pt unknown
- 2021-04-23 AU AU2021258542A patent/AU2021258542B2/en active Active
- 2021-04-23 IL IL297374A patent/IL297374B2/en unknown
-
2022
- 2022-03-17 US US17/696,997 patent/US11654115B2/en active Active
- 2022-10-19 ZA ZA2022/11461A patent/ZA202211461B/en unknown
-
2023
- 2023-04-14 US US18/300,739 patent/US12121614B2/en active Active
- 2023-09-29 JP JP2023169472A patent/JP7663647B2/ja active Active
-
2024
- 2024-09-17 US US18/887,301 patent/US20250235408A1/en active Pending
-
2025
- 2025-09-17 US US19/331,702 patent/US20260007608A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN116456968B (zh) | 生长抑素调节剂的制剂 | |
| ZA202211461B (en) | New delayed release composition for peroral administration | |
| JP2024153665A (ja) | Ｐ２ｘ３調節剤としての置換イミダゾピリジン化合物の結晶形態およびそれらの使用 | |
| JP2009526070A (ja) | Ｈｃｖプロテアーゼ阻害薬とｈｃｖポリメラーゼ阻害薬との組み合わせ、ならびにそれらに関連する処置の方法 | |
| JP2008514690A (ja) | Ｃ型肝炎感染の治療のための［ｄ−ｍｅａｌａ］３−［ｅｔｖａｌ］４−シクロスポリンの使用、及び当該［ｄ−ｍｅａｌａ］３−［ｅｔｖａｌ］４−シクロスポリンを含む医薬組成物 | |
| SE523481C2 (sv) | Läkemedelskomposition innehållande en HMG-CoA-reduktashämmare och ett organiskt salt med flervärd katjon | |
| JP2003531199A (ja) | アルキルおよびアリールアラニンｐ２部分を含むｃ型肝炎ウイルスに対する大員環ｎｓ３−セリンプロテアーゼ阻害剤 | |
| US10004719B1 (en) | Solid dispersion formulation | |
| CN1626093A (zh) | 奥卡西平包膜片剂 | |
| KR20080015401A (ko) | Ｃ5ａ 수용체 길항물질 | |
| WO2018067217A3 (en) | COMPOSITIONS COMPRISING SHORT PEPTIDES DERIVED FROM PEDF AND USES THEREOF | |
| JP2022511800A (ja) | 痛風または高尿酸血症を処置または予防するための化合物の結晶形態 | |
| WO2005037839A1 (fr) | Composes derives de norcantharidine, leurs procedes de preparation, les compositions les contenant et leurs utilisations. | |
| JP2023057082A (ja) | ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法 | |
| MX2022013070A (es) | Nueva composición en polvo seco para administración peroral. | |
| TW201522291A (zh) | 胍基苯甲酸酯化合物 | |
| WO2001082919A2 (en) | Methods of and compounds for inhibiting calpains | |
| CN110958880A (zh) | 固体分散制剂 | |
| US20250059231A1 (en) | Protease inhibitors | |
| US6197314B1 (en) | Impeding the extraction of active ingredients out of tablets | |
| JP2001064177A (ja) | ベンズアミド誘導体を有効成分とする製剤 | |
| WO2023044462A1 (en) | Cysteine protease inhibitor formulations and method of use thereof | |
| WO2011139636A1 (en) | Small molecule inhibitors of functions of the hiv-1 matrix protein | |
| CN1874778B (zh) | 由肠溶聚合物包衣的包含嘧啶-a-酮衍生物的药物制剂 | |
| CN113396138A (zh) | 吉卡宾、其药学上可接受的盐、其组合物和其使用方法 |